Eckert & Ziegler Bebig SA

What Eckert & Ziegler Bebig SA does

Eckert & Ziegler SE (which merged with Belgian Eckert & Ziegler BEBIG in February 2019 and now operates under the consolidated entity Eckert & Ziegler Bebig SA) is a TecDAX-listed German isotope technology company headquartered in Berlin with over 1,000 employees globally. The company is structured around three core business areas: cancer therapy (brachytherapy seeds, applicators, and radiation therapy devices), industrial radiometry (calibration sources, Krypton-85, Nickel-63), and nuclear-medical imaging (radioisotopes and radiopharmaceuticals for PET diagnostics). It manufactures and supplies medical radioisotopes including Gallium-68, Germanium-68, Lutetium-177, Yttrium-90, and Actinium-225, along with branded products such as the GalliaPharm Ge-68/Ga-68 radionuclide generator, I-125 and Pd-103 prostate brachytherapy seeds, Ru-106 eye applicators, SagiNova brachytherapy device, and Modular-Lab PharmTracer synthesis cassettes.

The business model is a B2B enterprise motion with direct sales to pharmaceutical companies developing radiopharmaceuticals, hospitals and clinics performing nuclear medicine and brachytherapy, and academic research institutions. Revenue is generated across five streams: radioisotope sales, CDMO services for radiopharmaceutical manufacturing under GMP conditions, sales of medical devices (brachytherapy seeds and applicators), manufacturing of hot cells and equipment, and specialized logistics for radioactive materials. Pricing is custom and quote-based, reflecting regulatory complexity and specialized handling. Manufacturing operations are anchored by GMP-certified facilities in Berlin-Buch, Braunschweig, and Leese (Germany), with a 50:50 joint venture (Qi Kang Medical Technology / QKM) with DongCheng Pharma operating a 9,500 m² production facility in Jintan, China.

The company converted its legal form to SE in 2024, completed a stock split in 2025, and spun off Pentixapharm AG in October 2024 to separate radiopharmaceutical drug development. Customer relationships span leading radiopharmaceutical developers including Telix Pharmaceuticals, SK Biopharmaceuticals, Actinium Pharmaceuticals, Sirtex Medical, Full-Life Technologies, POINT Biopharma, Ariceum, Bicycle Therapeutics, and Molecular Partners. Regulatory approvals span the EU, US (FDA), Japan, Canada, and Brazil, with MDR certification for prostate seeds and eye tumor treatment securing continued European market access.

Name

Eckert & Ziegler Bebig SA

Legal name

Eckert & Ziegler SE

Website

https://ezag.com

Company type

Public

Founded year

1997

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Eckert & Ziegler SE is a German isotope technology company providing medical radioisotopes, brachytherapy seeds and devices, and radiopharmaceutical CDMO services to pharmaceutical companies, hospitals, and research institutions globally for cancer therapy, nuclear-medical imaging, and industrial radiometry.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals and Medical Isotopes

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391), Irradiation Apparatus Manufacturing (334517)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industries

Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD), Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)

Keywords

• Medical radioisotope production
• Brachytherapy devices
• Radiopharmaceutical manufacturing
• Nuclear medicine supplies
• Radiation therapy products

Headquarters

HQ city

Seneffe

HQ country

Belgium

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Radioisotope Sales: Sale of medical radioisotopes including Gallium-68, Lutetium-177, Yttrium-90, Actinium-225, Germanium-68 to pharmaceutical companies and research institutions worldwide.
2. CDMO Services: Contract development and manufacturing services for radiopharmaceuticals. GMP-certified production for clinical trials and commercial supply.
3. Medical Devices: Sale of brachytherapy seeds (I-125, Pd-103), applicators, and radiation sources for cancer treatment.
4. Equipment Manufacturing: Hot cells and manufacturing equipment for radiopharmaceutical production facilities.
5. Radiopharmaceutical Logistics: Specialized logistics services for radioactive materials including global distribution.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Eckert & Ziegler SE manufactures and supplies medical radioisotopes (Gallium-68, Lutetium-177, Yttrium-90, Actinium-225, Germanium-68), brachytherapy products (I-125 and Pd-103 prostate seeds, I-125 ophthalmic seeds, Ru-106 eye applicators), the GalliaPharm Ge-68/Ga-68 radionuclide generator, the Modular-Lab PharmTracer synthesis device, and the SagiNova brachytherapy device. The group also provides contract development and manufacturing (CDMO) services for radiopharmaceuticals under GMP conditions. Customers are pharmaceutical companies, hospitals, clinics, and academic research institutions worldwide.

Product overview

Eckert & Ziegler Bebig SA operates as part of the Eckert & Ziegler Group, one of the world's largest providers of isotope technology for medical, scientific, and industrial use. The company offers a comprehensive portfolio of products and services organized across two main segments: Medical and Isotope Products. Core offerings include brachytherapy solutions (prostate seeds, eye seeds, applicators), radiopharmaceutical products (GalliaPharm® Ge-68/Ga-68 generators, therapeutic isotopes like Lutetium-177, Actinium-225, Yttrium-90), synthesis equipment (Modular-Lab PharmTracer), and CDMO contract manufacturing services. The company serves cancer therapy, nuclear-medical imaging, and industrial radiometry markets globally.

Differentiator

Problem solved

Functional benefit

Brands

• GalliaPharm: Ge-68/Ga-68 radionuclide generator for PET diagnostics
• Modular-Lab PharmTracer
• SagiNova

Products and services

• GalliaPharm Ge-68/Ga-68 Radionuclide Generator

Quantifiable outcome

• Global radioisotope supplier to leading pharmaceutical companies
• +1 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

20 partnerships are on record, tiered core and major.

• DongCheng Pharma (DC Pharma)coreStrategic or Co-development Partner · 11 June 2026Joint venture Qi Kang Medical Technology (QKM) for medical isotope production in China. 50:50 partnership. Production facility in Jintan, Changzhou with 9,500 m². Producing Germanium-68 initially, Actinium-225 planned for Phase 2.
• UJF (Czech Research Center)coreStrategic or Co-development Partner · 29 May 2026Joint development of Actinium-225 production. Opened high-tech Ac-225 production facility in June 2024. Significantly increased Ac-225 production volume in February 2026.
• Thor MedicalmajorStrategic or Co-development Partner · 28 May 2026Partnership announced for radiopharmaceutical development and production.
• Molecular PartnersmajorStrategic or Co-development Partner · 26 February 2026Cooperation for development of radiopharmaceutical products.
• SK BiopharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 3 December 2025Supply contract for Actinium-225 (Ac-225) for Korean pharmaceutical company's radiopharmaceutical pipeline.
• ArcheusmajorOEM/ Whitelabel/ Licensing Partner · 29 July 2025US manufacturing partner for Archeus' next-generation radiopharmaceutical.
• PentixapharmmajorStrategic or Co-development Partner · 24 April 2025Manufacturing agreement for Yttrium-90-based PentixaTher radiopharmaceutical.
• Actinium PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 25 March 2025Major Ac-225 supply for Actinium Pharmaceuticals' comprehensive clinical development program.
• AtomVie Global RadiopharmamajorStrategic or Co-development Partner · 20 March 2025Worldwide agreement for radiopharmaceutical services.
• Bicycle TherapeuticsmajorStrategic or Co-development Partner · 27 February 2025Strategic partnership for radiopharmaceutical manufacturing and development.
• Ariceum TherapeuticsmajorChannel Partner/ Reseller/ Distributor · 5 December 2024Global supply contract for Actinium-225.
• Telix PharmaceuticalscoreStrategic or Co-development Partner · 13 November 2024Cooperation and license agreement. Illuccix PSMA-PET diagnostic received German approval June 2025.
• Full-Life TechnologiesmajorChannel Partner/ Reseller/ Distributor · 23 January 2024Actinium-225 supply contract.
• ARTBIOmajorStrategic or Co-development Partner · 8 January 2024Partnership for manufacturing and development of radiopharmaceutical products.
• Ablaze PharmaceuticalsmajorChannel Partner/ Reseller/ Distributor · 23 October 2023Supply of Lutetium-177 for clinical trials.
• PharmaLogicmajorChannel Partner/ Reseller/ Distributor · 10 October 2023Reservation agreement for supply of radioisotopes.
• POINT BiopharmamajorChannel Partner/ Reseller/ Distributor · 4 April 2023Supply of Actinium-225.
• Alpha-9majorChannel Partner/ Reseller/ Distributor · 13 October 2022Reservation agreement for Actinium-225.
• NorthStar Medical RadioisotopesmajorStrategic or Co-development Partner · 11 October 2022Building Actinium-225 production line for NorthStar.
• PRECIRIXmajorChannel Partner/ Reseller/ Distributor · 20 July 2022Priority supply agreement for radiopharmaceutical development.

Scale indicators6 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Curium: One of the world's largest nuclear medicine companies producing SPECT/PET diagnostic isotopes and therapeutic radiopharmaceuticals. Directly comparable to EZAG in the radiopharmaceutical manufacturing and isotope supply business.
• NorthStar Medical Radioisotopes: US-based producer of medical radioisotopes including Mo-99/Tc-99m and is building Ac-225 production capacity — a direct competitor in medical isotope production where EZAG is also building Ac-225 capacity.
• Cardinal Health (Nuclear Pharmacy Services): Operates the largest radiopharmaceutical distribution network in the US, supplying unit-dose radiopharmaceuticals to hospitals. Directly comparable in the radiopharmacy logistics and distribution layer of EZAG's business.
• ITM Isotope Technologies Munich SE: Specialist in medical radioisotopes (notably Lu-177 / no-carrier-added) and radiopharmaceutical manufacturing with a global production network. A direct competitor in the medical isotope and CDMO market.
• PETNET Solutions (Siemens Healthineers): A leading PET radiopharmacy network distributing FDG and other PET tracers in the US and UK. Directly comparable in the PET tracer distribution/CDMO layer overlapping with EZAG's imaging tracer business.

Broad incumbents

• Bracco Imaging: Global imaging diagnostic company with a growing radiopharmaceutical portfolio. Broad incumbent in the diagnostic imaging and nuclear medicine space overlapping with EZAG's imaging tracer business.
• Lantheus Holdings: Leading radiopharmaceutical-focused company with diagnostic and therapeutic products (e.g., PYLARIFY PSMA-PET, Point Biologics acquired from POINT). Comparable to EZAG in radiopharmaceutical development, manufacturing, and commercialization.
• Siemens Healthineers (PET/Nuclear Medicine): Major medical technology company with a strong PET imaging and radiopharmacy equipment/services business. Comparable in the nuclear medicine imaging and isotope ecosystem where EZAG's Ga-68 generators and synthesis modules are used.
• Bayer (Radiology / Curium stake): Through its prior ownership of Curium and its radiology business, Bayer is a broad incumbent in radiopharmaceuticals and imaging. Comparable in the broader radiopharma industry context, including theranostics.

Emerging players

• Telix Pharmaceuticals: Radiopharmaceutical company developing diagnostic and therapeutic products (Illuccix PSMA-PET), with which EZAG has a cooperation and license agreement. Comparable as a customer/partner and as a developer of products using EZAG-supplied isotopes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/eckert-and-ziegler-se

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A7 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eckert & Ziegler Bebig SA